March 18, 2007 -- Biotech suffered a small decline over the last week, with the Centient Biotech 200™ slipping 20 points lower to 3802, a loss of .53% on the week. The breadth numbers, however, paint a somewhat weaker picture, while the IPO market was fairly quiet. Only the advent of Tongjitang Chinese Medicines broke the IPO calm. Micromet was the biggest percentage winner on news of an out-licensing deal; La Jolla Pharma continued to rise following positive results for lupus drug Riquent; Critical Therapeutics moved up on a co-promote agreement for asthma drug Zyflow; and Avanir climbed higher on news of a boardroom shuffle. More details...
